Maternal Antiviral Prophylaxis to Prevent Perinatal Transmission of Hepatitis B Virus in Thailand (iTAP)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01745822 |
|
Recruitment Status :
Completed
First Posted : December 10, 2012
Results First Posted : March 5, 2021
Last Update Posted : March 5, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Chronic hepatitis B (CHB) infection is complicated by cirrhosis and liver cancer. In Thailand, 7% of adults are chronically infected by Hepatitis B virus (HBV). The risk of perinatal transmission of HBV is about 12% when a mother has a high HBV load in her plasma, even if her infant receive specific immunoglobulin and vaccine.
The hypothesis of this study is that a potent antiviral, tenofovir, can decrease HBV load in HBV infected pregnant women and therefore reduce the risk of perinatal transmission/ Pregnant women participating in this study will receive tenofovir or placebo during the last trimester of pregnancy and two months postpartum. The risk of perinatal transmission will be compared between the two groups.
The results of the study will help define policy to manage HBV infected pregnant women to prevent perinatal transmission.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Hepatitis B Chronic Infection Pregnancy | Drug: tenofovir disoproxil fumarate Drug: placebo | Phase 3 |
This is a phase III, placebo controlled, double blind, randomized clinical trial to assess the efficacy and safety of tenofovir disoproxil fumarate (TDF) given from 28 weeks' gestation until 2 months postpartum to pregnant women with Hepatitis B (HB) virus (HBV) chronic infection and positive for HB s and e antigen to prevent perinatal transmission of HBV to their infants. All infants will receive HBV passive (HB specific immunoglobulin) and active (vaccine) immunization.
Chronic hepatitis B (CHB) infection is complicated by cirrhosis and hepatocellular carcinoma (HCC), the 10th leading cause of death worldwide.
In 2011, about 7% of adults in Thailand were HBsAg carriers. Infant hepatitis B (HB) immunization and HB immune globulin (HBIg) administered at birth effectively prevent most mother-to-child transmission (MTCT) of HBV. However, about 12% of mothers with high load of HBV transmit the virus to their infants, despite active and passive immunization.
Studies have suggested that antiviral treatment at the end of pregnancy and during early postpartum can reduce the risk of transmission to the child. A potential limitation to this approach is the risk of hepatic disease exacerbation following discontinuation of antiviral treatment postpartum, and this risk has not been properly evaluated. No randomized clinical trials have adequately demonstrated the efficacy and safety of maternal antiviral treatment the prevention of mother to child transmission of HBV. This is the reason why this approach is not currently recommended by the Associations for the Study of Liver Diseases.
We hypothesize that a potent antiviral, tenofovir, can decrease HBV viral load in HBV infected pregnant women and therefore reduce the risk of perinatal transmission, before infants are definitely protected by passive-active immunization. We also hypothesize that only moderate exacerbations of liver disease will be observed after discontinuation of a short antiviral course (5 months). While the primary objective of the study is to assess the efficacy of tenofovir versus placebo for the prevention of perinatal transmission, an important secondary objective is the assessment of the risk of postpartum hepatic disease exacerbation.
Within 2 years, 328 women and their infants will be enrolled from public hospitals in Thailand and randomized to receive either tenofovir disoproxil fumarate or matching placebo from 28 weeks of pregnancy until 2 months postpartum. Mothers and infants will be followed until one year postpartum.
The primary endpoint will be the detection of HBsAg and HBV DNA in infants at six months of life. An interim analysis will be conducted when half of the outcomes are available.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 654 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Prevention |
| Official Title: | Phase 3, Randomized Clinical Trial to Assess the Efficacy and Safety of Tenofovir in Hepatitis B Virus Infected, s and e Antigen Positive, Pregnant Women to Prevent Perinatal Transmission Despite Infant Passive-active HBV Immunization. |
| Study Start Date : | January 2013 |
| Actual Primary Completion Date : | December 2016 |
| Actual Study Completion Date : | October 2018 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Tenofovir disoproxil fumarate
tenofovir disoproxil fumarate, 300 mg tablets
|
Drug: tenofovir disoproxil fumarate
administration: tablet 300 mg, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum
Other Names:
|
|
Placebo Comparator: Placebo
matching placebo (of tenofovir disoproxil fumarate)
|
Drug: placebo
administration: one tablet, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum |
- Percentage of Infants With Hepatitis B Infection at 6 Months of Age [ Time Frame: 6 months of age ]Infection is defined as a HBsAg positive test confirmed by detectable HBV DNA
- Percentage of Participants With Adverse Events [ Time Frame: from enrollment (28 weeks' gestation) to 12 months postpartum ]Occurrence of maternal and infant adverse events, including maternal and infants Serious Adverse Events (as defined by the International Conference on Harmonization Good Clinical Practice) and NIH Division of AIDS grade 3/4 signs and symptoms, regardless of their relatedness to the study treatment.
- Percentage of Participants With Flares After Study Treatment Interruption [ Time Frame: Following planned discontinuation of study treatment up to 12 months postpartum ]Flare, or acute exacerbation of hepatitis B, after study treatment interruption is defined as an Alanine Aminotransferase plasma level above 300 IU/mL
- Percentage of Infants With Hepatitis B Infection at or After 6 Months Through 12 Months of Age [ Time Frame: at or after 6 months through 12 months of age ]Infants will be considered HBV infected if at any time point at or after 6 months through 12 months of age, a sample tests positive for HBsAg and HBV DNA
- Weight, Height and Head Circumference for Age [ Time Frame: assessed at 6 months and 12 months of age, 6 months reported ]Weight, length/height and head circumference WHO Z scores are measures of relative weight, height and head circumference adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Pregnancy
- At least 18 years of age
- Negative Human Immunodeficiency Virus (HIV) serology
- Positive HBsAg and hepatitis B e antigen (HBeAg) tests
- Gestational age of 28 weeks (+ or - 10 days) as determined by obstetrician
- Alanine Aminotransferase (ALT)≤30 U/L, confirmed ≤60 U/L on a subsequent blood draw
- Agreeing to bring their infants at the planned study visits at one study site until one year after delivery and to inform the site investigators if they plan to move to another place and not be able to return to the clinic.
- Understanding the need for adequate infant immunization and agreeing to the blood draws from their infants and the need for close follow up to manage possible exacerbation of hepatitis.
Exclusion Criteria:
- History of tenofovir treatment at any time, or any other anti-HBV treatment during the current pregnancy
- Creatinine clearance <50 ml/min, calculated using the Cockcroft-Gault formula
- Dipstick proteinuria>1+ (>30 mg/dL) or normoglycemic glucosuria confirmed on two separate occasions
- Positive serology for Hepatitis C infection less than 12 months prior to enrollment
- Evidence of pre-existing fetal anomalies incompatible with life
- Any concomitant condition or treatment that, in the view of the clinical site investigator, would contraindicate participation or satisfactory follow up in the study.
- Concurrent participation in any other clinical trial without written agreement of the two study teams
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01745822
Show 17 study locations
| Principal Investigator: | Gonzague Jourdain, MD, PhD | Institut de Recherche pour le Developpement |
Documents provided by GONZAGUE JOURDAIN, Institut de Recherche pour le Developpement:
Publications of Results:
Other Publications:
| Responsible Party: | GONZAGUE JOURDAIN, Chargé de recherches, Institut de Recherche pour le Developpement |
| ClinicalTrials.gov Identifier: | NCT01745822 |
| Other Study ID Numbers: |
U01HD071889 ( U.S. NIH Grant/Contract ) U01HD071889 ( U.S. NIH Grant/Contract ) |
| First Posted: | December 10, 2012 Key Record Dates |
| Results First Posted: | March 5, 2021 |
| Last Update Posted: | March 5, 2021 |
| Last Verified: | February 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Plan Description: | Pending completion of analysis planned in the protocol |
|
Hepatitis B Hepatitis B sAg Hepatitis B eAg pregnancy |
|
Hepatitis A Hepatitis B Hepatitis B, Chronic Hepatitis Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases Infections Enterovirus Infections Picornaviridae Infections RNA Virus Infections Blood-Borne Infections |
Communicable Diseases Hepadnaviridae Infections DNA Virus Infections Hepatitis, Chronic Tenofovir Antiviral Agents Anti-Infective Agents Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents |